GREATER LIKELIHOOD OF REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB, IN PATIENTS WITH HIGHER LP(A) LEVELS
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)30558-8
Abstract: There is genetic and epidemiological evidence demonstrating the association between Lp(a) levels and cardiovascular disease. While evolocumab reduces Lp(a) by 25-30%, the impact of PCSK9 inhibition on plaque at different Lp(a) levels is unknown. GLAGOV… read more here.
Keywords: regression coronary; greater likelihood; pcsk9 inhibitor; likelihood regression ... See more keywords